Polygenic Score (PGS) ID: PGS000873

Predicted Trait
Reported Trait Breast cancer
Mapped Trait(s) breast carcinoma (EFO_0000305)
Released in PGS Catalog: Aug. 26, 2021
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name SNP143
Development Method
Name Genome-wide significant variants
Parameters NR
Variants
Original Genome Build GRCh37
Number of Variants 143
Effect Weight Type log(OR)
PGS Source
PGS Catalog Publication (PGP) ID PGP000216
Citation (link to publication) Brentnall AR et al. Int J Cancer (2019)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
139,274 individuals (100%)
PGS Evaluation
Not Reported: 90%
East Asian: 10%
10 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST004988
Europe PMC: 29059683
139,274 individuals European NR

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM002456 PSS001111|
Ancestry Not Reported|
2,073 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Breast cancer Odds Ratio (OR, per interquartile range unit change): 2.12 [1.81, 2.49] Age
PPM002458 PSS001105|
Ancestry Not Reported|
2,021 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Estrogen-receptor positive breast cancer Odds Ratio (OR, per interquartile range unit change): 2.17 [1.83, 2.58] Age
PPM002460 PSS001108|
Ancestry Not Reported|
1,707 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Estrogen-receptor negative breast cancer Odds Ratio (OR, per interquartile range unit change): 1.86 [1.18, 2.91] Age
PPM002462 PSS001113|
Ancestry Not Reported|
1,991 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Invasive breast cancer Odds Ratio (OR, per interquartile range unit change): 2.14 [1.79, 2.55] Age
PPM002464 PSS001112|
Ancestry Not Reported|
1,750 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Breast ductal cancer in situ Odds Ratio (OR, per interquartile range unit change): 2.0 [1.46, 2.75] Age
PPM002466 PSS001107|
Ancestry Not Reported|
1,956 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Invasive estrogen-receptor positive breast cancer Odds Ratio (OR, per interquartile range unit change): 2.55 [1.86, 2.7] Age
PPM002468 PSS001106|
Ancestry Not Reported|
1,733 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Estrogen-receptor positive breast ductal cancer in situ Odds Ratio (OR, per interquartile range unit change): 1.84 [1.3, 2.6] Age
PPM002470 PSS001110|
Ancestry Not Reported|
1,694 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Invasive estrogen-receptor negative breast cancer Odds Ratio (OR, per interquartile range unit change): 1.44 [0.84, 2.47] Age
PPM002471 PSS001109|
Ancestry Not Reported|
1,681 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Estrogen-receptor negative breast ductal cancer in situ Odds Ratio (OR, per interquartile range unit change): 3.12 [1.41, 6.88] Age
PPM002457 PSS001111|
Ancestry Not Reported|
2,073 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Breast cancer Odds Ratio (OR, per interquartile range unit change): 2.06 [1.75, 2.42] Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density
PPM002459 PSS001105|
Ancestry Not Reported|
2,021 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Estrogen-receptor positive breast cancer Odds Ratio (OR, per interquartile range unit change): 2.11 [1.78, 2.51] Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density
PPM002461 PSS001108|
Ancestry Not Reported|
1,707 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Estrogen-receptor negative breast cancer Odds Ratio (OR, per interquartile range unit change): 1.81 [1.16, 2.84] Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density
PPM002463 PSS001113|
Ancestry Not Reported|
1,991 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Invasive breast cancer Odds Ratio (OR, per interquartile range unit change): 2.07 [1.74, 2.48] Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density
PPM002465 PSS001112|
Ancestry Not Reported|
1,750 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Breast ductal cancer in situ Odds Ratio (OR, per interquartile range unit change): 1.93 [1.41, 2.65] Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density
PPM002469 PSS001106|
Ancestry Not Reported|
1,733 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Estrogen-receptor positive breast ductal cancer in situ Odds Ratio (OR, per interquartile range unit change): 1.77 [1.24, 2.51] Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density
PPM002472 PSS001109|
Ancestry Not Reported|
1,681 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Estrogen-receptor negative breast ductal cancer in situ Odds Ratio (OR, per interquartile range unit change): 2.99 [1.35, 6.6] Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density
PPM002467 PSS001107|
Ancestry Not Reported|
1,956 individuals
PGP000216 |
Brentnall AR et al. Int J Cancer (2019)
Reported Trait: Invasive estrogen-receptor positive breast cancer Odds Ratio (OR, per interquartile range unit change): 2.18 [1.81, 2.63] Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density
PPM018697 PSS011069|
East Asian Ancestry|
495 individuals
PGP000494 |
Ho PJ et al. Elife (2023)
|Ext.
Reported Trait: Breast cancer AUROC: 0.6 [0.58, 0.63] Hazard ratio (HR, high vs low tertile): 2.68 [1.97, 3.66] age at recruitment

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS001105 Breast cancer diagnosis (invasive or ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER+ subtype
[
  • 353 cases
  • , 1,668 controls
]
,
0.0 % Male samples
Not reported PROCAS
PSS001106 Breast cancer diagnosis (ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER+ subtype
[
  • 65 cases
  • , 1,668 controls
]
,
0.0 % Male samples
Not reported PROCAS
PSS001107 Breast cancer diagnosis (invasive) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER+ subtype
[
  • 288 cases
  • , 1,668 controls
]
,
0.0 % Male samples
Not reported PROCAS
PSS001108 Breast cancer diagnosis (invasive or ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER- subtype.
[
  • 39 cases
  • , 1,668 controls
]
,
0.0 % Male samples
Not reported PROCAS
PSS001109 Breast cancer diagnosis (ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER- subtype.
[
  • 13 cases
  • , 1,668 controls
]
,
0.0 % Male samples
Not reported PROCAS
PSS001110 Breast cancer diagnosis (invasive) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems. All cases had ER- subtype.
[
  • 26 cases
  • , 1,668 controls
]
,
0.0 % Male samples
Not reported PROCAS
PSS001111 Breast cancer diagnosis (invasive or ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems
[
  • 405 cases
  • , 1,668 controls
]
,
0.0 % Male samples
Median = 60.0 years Not reported PROCAS
PSS001112 Breast cancer diagnosis (ductal carcinoma in situ [DCIS]) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems
[
  • 82 cases
  • , 1,668 controls
]
,
0.0 % Male samples
Not reported PROCAS
PSS001113 Breast cancer diagnosis (invasive) was at the entry screen (10/2009–06/2015) or subsequently before January 5, 2017, and was ascertained through monthly updates from (National Health Service) Breast Screening Systems
[
  • 323 cases
  • , 1,668 controls
]
,
0.0 % Male samples
Not reported PROCAS
PSS011069 495 individuals,
0.0 % Male samples
Median = 53.0 years
IQR = [48.0, 59.0] years
East Asian
(Chinese)
SCHS